<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00432562</url>
  </required_header>
  <id_info>
    <org_study_id>530-01</org_study_id>
    <nct_id>NCT00432562</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.</brief_title>
  <official_title>A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion (ANX-530) in Patients With Advanced Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mast Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Synteract, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thywill Latam Solutions SRL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OCASA Soluciones Logísticas S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mast Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a randomized, single dose crossover comparison of the investigational product
      with a Reference Product (vinorelbine tartrate injection, NAVELBINE®). The primary objective
      was to demonstrate the equivalence of ANX-530 and the Reference Product, NAVELBINE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ANX-530 (vinorelbine tartrate injectable emulsion), an investigational drug, is an
      oil-in-water emulsion of vinorelbine tartrate composed of an oil phase and emulsifier
      dispersed in an aqueous solution. ADVENTRX Pharmaceuticals, Inc. of San Diego, California,
      developed ANX-530 as a vinorelbine tartrate formulation to be used in clinical settings where
      Vinorelbine Tartrate Injection (NAVELBINE) is indicated. Nonclinical toxicology studies
      suggest either equivalent or less toxicity of ANX-530 compared to Reference Product. In
      particular, ANX-530 caused less vein toxicity in a rabbit vein irritation model, suggesting
      ANX-530 could potentially cause less venous irritation than NAVELBINE in a clinical setting.
      ADVENTRX is investigating whether ANX-530 could substitute for NAVELBINE in these settings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0-144 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentratio-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
    <description>Determined Using the Linear Trapezoidal Rule</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
    <description>AUCinf = AUClast + (Clast/lamda z)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of AUCinf Based on Extrapolation (AUCextrap)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Elimination Rate Constant Associated With the Terminal Portion of the Curve (λ z)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
    <description>Estimated via linear regression of the time versus log concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed Terminal Elimination Half-Life (t1/2)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
    <description>t1/2 = [ln(2)/λ z]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Last Measurable Concentration (Tlast)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Quantifiable Drug Concentration (Clast)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Residence Time (MRTinf)</measure>
    <time_frame>0-144 hours post-dose</time_frame>
    <description>MRT = (AUMCinf)/(AUCinf)</description>
  </primary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Non-Hodgkins Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine Tartrate</intervention_name>
    <description>Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.</description>
    <other_name>Exelbine (proposed)</other_name>
    <other_name>ANX-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Advanced cancer potentially sensitive to vinorelbine:

          -  Breast cancer.

          -  Stage 3 or 4 non-small cell lung cancer.

          -  Non-Hodgkins lymphoma.

          -  Cancer of other histologic type, sensitive to vinca alkaloids.

          -  Rare tumor type with no standard treatment, for which single agent vinorelbine is
             appropriate therapy.

          -  Failure of standard treatment(s) of the tumor.

          -  Life expectancy of at least three months.

          -  ECOG performance level 0-2 or Karnofsky score 100-70.

          -  Hematological and serum chemistry results with defined ranges.

          -  Willingness and ability to provide written informed consent.

        Exclusion Criteria:

          -  Pregnancy or lactation. In a woman of childbearing potential, a positive pregnancy
             test result, no pregnancy test result, or no use of reliable contraception, at
             baseline. A postmenopausal woman will be considered to be of childbearing potential
             until there has been amenorrhea for at least 12 consecutive months.

          -  Previous treatment with vinorelbine or mitomycin.

          -  Any history suggesting or demonstrating resistance to, lack of response to, or
             intolerance of any prior vinca alkaloid treatment.

          -  Active infection.

          -  Prior anticancer therapy completed within four weeks prior to the first day of study
             treatment.

          -  Failure to have recovered from any toxicity of previous cancer treatment (patients
             with alopecia will not be excluded).

          -  Participation in another experimental drug study within four weeks prior to the first
             day of study treatment.

          -  Requirement for any concomitant chemotherapeutic agent other than the study
             medication.

          -  Any investigator judgment that the individual would not be an appropriate study
             subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lino Arboit, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Centro Oncológico de Integración Regional - COIR.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerardo F Arroyo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Privado De Santa Clara De Asis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cesar R Blajman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isis Clínica Especializada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matias Chacon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Médico Espcializado Alexander Fleming</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis E Fein, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Oncológico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugo R. Requejo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Regional De Concepción</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edgar P Quintana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIMA Salud</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2007</study_first_submitted>
  <study_first_submitted_qc>February 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2007</study_first_posted>
  <results_first_submitted>January 19, 2012</results_first_submitted>
  <results_first_submitted_qc>January 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2012</results_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <name_title>Chief Executive Officer</name_title>
    <organization>Adventrx Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>STUDIED PERIOD:
First Patient Enrolled: 22 March 2007 Last Patient Completed: 02 November 2007 Study patients were enrolled at seven study sites in Argentina.</recruitment_details>
      <pre_assignment_details>Pre-screening data was not collected for this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ANX-530/Navelbine</title>
          <description>Patients were randomly assigned to receive a single intravenous (IV) dose of 30 mg/m2 of ANX 530 in the first study period, then one week later patients crossed over to receive a single IV dose of 30 mg/m2 of Navelbine in the second study period.</description>
        </group>
        <group group_id="P2">
          <title>Navelbine/ANX-530</title>
          <description>Patients were randomly assigned to receive a single intravenous (IV) dose of 30 mg/m2 of Navelbine in the first study period, then one week later patients crossed over to receive a single IV dose of 30 mg/m2 of ANX-530 in the second study period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ANX-530/Navelbine</title>
          <description>Patients were randomly assigned to receive a single intravenous (IV) dose of 30 mg/m2 of ANX 530 in the first study period, then one week later patients crossed over to receive a single IV dose of 30 mg/m2 of Navelbine in the second study period.</description>
        </group>
        <group group_id="B2">
          <title>Navelbine/ANX-530</title>
          <description>Patients were randomly assigned to receive a single intravenous (IV) dose of 30 mg/m2 of Navelbine in the first study period, then one week later patients crossed over to receive a single IV dose of 30 mg/m2 of ANX-530 in the second study period.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.2" spread="12.77"/>
                    <measurement group_id="B2" value="58.0" spread="13.34"/>
                    <measurement group_id="B3" value="60.2" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
        <time_frame>0-144 hours post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Maximum Observed Plasma Concentration (Tmax)</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.13"/>
                    <measurement group_id="O2" value="0.34" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax)</title>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" spread="108"/>
                    <measurement group_id="O2" value="223" spread="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentratio-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast)</title>
        <description>Determined Using the Linear Trapezoidal Rule</description>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentratio-Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUClast)</title>
          <description>Determined Using the Linear Trapezoidal Rule</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="757.8" spread="363.7"/>
                    <measurement group_id="O2" value="716.1" spread="272.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf)</title>
        <description>AUCinf = AUClast + (Clast/lamda z)</description>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf)</title>
          <description>AUCinf = AUClast + (Clast/lamda z)</description>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="810.1" spread="400.9"/>
                    <measurement group_id="O2" value="718.5" spread="223.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of AUCinf Based on Extrapolation (AUCextrap)</title>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of AUCinf Based on Extrapolation (AUCextrap)</title>
          <units>% of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.23" spread="2.54"/>
                    <measurement group_id="O2" value="4.72" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Elimination Rate Constant Associated With the Terminal Portion of the Curve (λ z)</title>
        <description>Estimated via linear regression of the time versus log concentration</description>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Observed Elimination Rate Constant Associated With the Terminal Portion of the Curve (λ z)</title>
          <description>Estimated via linear regression of the time versus log concentration</description>
          <units>hr-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0160" spread="0.0044"/>
                    <measurement group_id="O2" value="0.0187" spread="0.0062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Observed Terminal Elimination Half-Life (t1/2)</title>
        <description>t1/2 = [ln(2)/λ z]</description>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Observed Terminal Elimination Half-Life (t1/2)</title>
          <description>t1/2 = [ln(2)/λ z]</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.50" spread="12.43"/>
                    <measurement group_id="O2" value="40.48" spread="13.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Last Measurable Concentration (Tlast)</title>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Time of Last Measurable Concentration (Tlast)</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.83" spread="12.93"/>
                    <measurement group_id="O2" value="141.79" spread="12.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Last Quantifiable Drug Concentration (Clast)</title>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Drug Concentration (Clast)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.819" spread="0.834"/>
                    <measurement group_id="O2" value="0.824" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Residence Time (MRTinf)</title>
        <description>MRT = (AUMCinf)/(AUCinf)</description>
        <time_frame>0-144 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANX-530</title>
          </group>
          <group group_id="O2">
            <title>Navelbine</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRTinf)</title>
          <description>MRT = (AUMCinf)/(AUCinf)</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.39" spread="7.90"/>
                    <measurement group_id="O2" value="31.31" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs and their treatment were documented from the time of the first dose of study medication until 30 days after the last dose. Mild, moderate and severe AEs not related to study treatment were followed for approx 30 days after the last study drug dose.</time_frame>
      <desc>Events that were serious, life threatening or related to study treatment were followed until resolution, downgrading of an SAE to non-serious, subject death, start of new cancer therapy or re-assessment of the event’s relationship to study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>ANX-530/Navelbine</title>
          <description>Patients were randomly assigned to receive a single intravenous (IV) dose of 30 mg/m2 of ANX 530 in the first study period, then one week later patients crossed over to receive a single IV dose of 30 mg/m2 of Navelbine. Serious Adverse Events are reported by treatment-sequence group and not by study therapy group.</description>
        </group>
        <group group_id="E2">
          <title>Navelbine/ANX-530</title>
          <description>Patients were randomly assigned to receive a single intravenous (IV) dose of 30 mg/m2 of Navelbine in the first study period, then one week later patients crossed over to receive a single IV dose of 30 mg/m2 of ANX-530. Serious Adverse Events are reported by treatment-sequence group and not by study therapy group.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>GENITAL INFECTION FEMALE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>STUPOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>INFUSION SITE PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of data related to the Study, including publication in special medical magazines, or the disclosure at medical congresses shall be previously authorized in writing by the Sponsor, whereby the Principal Investigator should present the material with an anticipation of not less than 60 days as from the publication or medical congress. The Sponsor decides upon the authorship of any publication related to the Study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Executive Officer</name_or_title>
      <organization>Adventrx Pharmaceuticals</organization>
      <phone>858-768-6325</phone>
      <email>culley@adventrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

